MTST

MetaStat Inc.

USOTC

Add Alert

MTST

MetaStat Inc.

USOTC

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

lowfloatmaster Free

06/21/18 9:51 AM

Post #76

CRAZY GOOD NEWS TODAY . PLUS LOW FLOAT

Renee

10/07/15 9:15 AM

Post #75

MTST: effective Oct 8,2015 a one for 15 reverse split:

http://otce.finra.org/DLSymbolNameChanges

basssque

09/03/15 12:37 PM

Post #74

Re: #71: @makinezmoney - NEWS: Positive results of MenaCalc

Things are looking good! I'm pleased so far smile

hal8445

09/02/15 5:06 PM

Post #73

Moon shot for MTST today?

O/S: 27,630,052 (a/o May 21, 2015)
A/S: 150,000,000 (a/o February 24, 2015)

http://www.otcdynamics.com/$mtst-metastat-inc-promotional-campaign-starting-sep-2-2015-406-pm-cst/

Good luck

makinezmoney Free

09/02/15 9:59 AM

Post #72

NEWS: Positive results of MenaCalc

http://content.stockpr.com/metastat/news/2015-09-02_MetaStat_Inc_Announces_Positive_Results_of_a_372.pdf

makinezmoney Free

09/02/15 8:49 AM

Post #71

NEWS: Positive results of MenaCalc

http://content.stockpr.com/metastat/news/2015-09-02_MetaStat_Inc_Announces_Positive_Results_of_a_372.pdf

$Pistol Pete$ Free

08/18/15 3:32 PM

Post #70

Re: #69: @basssque - Form 4 just issued. CEO/president bought 10,000

Thank you

basssque

08/18/15 3:31 PM

Post #69

Re: #63: @$Pistol Pete$ - http://finance.yahoo.com/news/metastat-inc-announces-issuance-u-133000487.html

Form 4 just issued. CEO/president bought 10,000 more shares.

basssque

07/24/15 4:10 PM

Post #68

Added again at .24 today!
Getting everything at bargain basement prices lately! Loving it!

basssque

07/22/15 12:10 PM

Post #67

Re: #63: @$Pistol Pete$ - http://finance.yahoo.com/news/metastat-inc-announces-issuance-u-133000487.html

Nice value buy here at .26 today. Someone dumped 150k this morning.
Snagged some here, very pleased with my investment at this pps!
GLTA

basssque

07/08/15 11:28 AM

Post #66

Novel Metastatic Risk-Based Technology Could Transform Cancer Treatment Protocol

http://seekingalpha.com/article/3309435-novel-metastatic-risk-based-technology-could-transform-cancer-treatment-protocol

Nogabev

08/15/14 12:51 PM

Post #65

Re: #64: @mattp_160 - Anyone still in this one? Glad I was

I sold and made some money on this not much but better than a loss.
I bough back in at .98 and just watched it drop like a rock off the edge of the Grand Canyon.
But as it is said you are already in so "Patience Grasshopper"
Cheers

mattp_160

08/11/14 10:20 PM

Post #64

Anyone still in this one? Glad I was smart and cut my losses while I still had money.

$Pistol Pete$ Free

06/30/14 1:07 PM

Post #63

http://finance.yahoo.com/news/metastat-inc-announces-issuance-u-133000487.html

$Pistol Pete$ Free

06/30/14 1:04 PM

Post #62

http://finance.yahoo.com/news/biotech-breakthroughs-brings-powerful-cancer-120000758.html

Peter

$Pistol Pete$ Free

06/30/14 12:45 PM

Post #61

Re: #54: @Nogabev - I had a great conversation with Mr. Winston

That is good. They do care for the investors.

Peter

smoketrain Free

06/30/14 12:44 PM

Post #60

Re: #59: @$Pistol Pete$ - Excellent company to invest at this low PPS.

I am hoping so :)

$Pistol Pete$ Free

06/30/14 12:43 PM

Post #59

Re: #56: @smoketrain - NEWS NEWS $$$

Excellent company to invest at this low PPS.

Peter

$Pistol Pete$ Free

06/30/14 12:42 PM

Post #58

http://finance.yahoo.com/news/biotech-breakthroughs-brings-powerful-cancer-120000758.html

$Pistol Pete$ Free

06/30/14 12:41 PM

Post #57

http://finance.yahoo.com/news/goldman-small-cap-research-issues-120000148.html

smoketrain Free

06/04/14 12:50 PM

Post #56

NEWS NEWS $$$

Nogabev

05/22/14 12:29 AM

Post #55

Re: #54: @Nogabev - I had a great conversation with Mr. Winston

I meant Warren Lau not Winston

Nogabev

05/21/14 1:30 PM

Post #54

I had a great conversation with Mr. Winston Lau yesterday. I was kind of surprise to get an answer when I called.
we had a very good conversation which made me still believe in the technology that this company has created.
He did point me to the article on yahoo financial that indicated the future of this technology.
Therefore I am still holding and hoping that this technology will take off as it should.

mattp_160

05/13/14 2:05 PM

Post #53

Good question. Im out, cut my loses and moved on.

johnnyfrick Free

05/10/14 1:05 PM

Post #52

when will this pos move

mattp_160

04/03/14 10:58 PM

Post #51

Re: #50: @Nogabev - What is going on with this stock.

Stock has been bouncing around all over lately. I'm still holding my shares. Don't have any free powder to buy more. I almost lost it when it hit in the 1.15's. We seem to bounce all over lately I don't get it. Just waiting for some good news to come out so this can pop.

Nogabev

04/03/14 1:50 PM

Post #50

What is going on with this stock.
Also, this is a dead board

mattp_160

03/24/14 12:13 PM

Post #49

Looks like dilution to me. Company is dumping shares to pay for something?

mattp_160

03/17/14 6:57 PM

Post #48

Just hanging out, not doing much. This one I have tucked away in my account for the long haul. I see big things happening later this year and into next year.

smoketrain Free

03/11/14 11:15 AM

Post #47

Re: #46: @airjay - PR can say all they want. Do they

Their financials are on their website, you are free to examine it and report back, we would appreciate your analogy.

airjay

03/11/14 11:13 AM

Post #46

Re: #45: @smoketrain - Thats why:

PR can say all they want. Do they have enough funding/investment in order to complete their diagnostic/therapeutic development? They might not even be able to see their products go public.

smoketrain Free

03/11/14 10:58 AM

Post #45

Re: #44: @airjay - What makes you guys think that this stock

Thats why:
from the recent PR
" has products that have been shown to have promising results, and the company is expected to begin revenue generation in 2015, with an expected nationwide rollout of its service by 2018"

airjay

03/08/14 2:51 PM

Post #44

What makes you guys think that this stock is on the rise? All companies have news about themselves to make them look good.any specific reasons why you believe in this company so much?

smoketrain Free

03/07/14 9:06 PM

Post #43

Re: #42: @mattp_160 - I see nothing but good things coming in

Exactly. This is a $20+ once marketing is in full gear.

mattp_160

03/07/14 9:05 PM

Post #42

Re: #41: @smoketrain - Its a good time to do so. Next

I see nothing but good things coming in the future for MTST.

smoketrain Free

03/07/14 9:00 PM

Post #41

Re: #40: @mattp_160 - +1. Thinking about buying another thousand shares in

Its a good time to do so. Next pr/news will catapult to $3+

mattp_160

03/07/14 8:58 PM

Post #40

Re: #39: @smoketrain - Holding long and strong MTST $$$$

+1. Thinking about buying another thousand shares in the low 1.40s.

smoketrain Free

03/07/14 3:57 PM

Post #39

Holding long and strong MTST $$$$

holdithigh Free

03/06/14 4:42 PM

Post #38

Re: #37: @mattp_160 - Just because people aren't posting on this board

yep, because it's not part of the yahoo message board and this ones very quiet is actually a good thing.

I'm not at all concern because this stock trades minimal. If it was a pump and dump the stock would have higher volumes and the share price would work itself down to a near bankrupt price (.01-.05). Also, very erratic price swings which tells me again, theres "not" a lot of share dumping going on.

nibble nibble!

hold

mattp_160

03/06/14 9:06 AM

Post #37

Just because people aren't posting on this board doesn't mean they aren't investing. I like that it's not being pumped up and bashed by hundreds of people.

read the news, that's why I'm holding long term here. Big things coming down the pipe for us.

mattp_160

03/06/14 7:13 AM

Post #36

Re: #35: @airjay - This board got quiet realllllll fast LOL

Still here and holding. Sorry I dont post alot on ihubber.

airjay

03/06/14 2:09 AM

Post #35

This board got quiet realllllll fast LOL

airjay

03/05/14 1:42 PM

Post #34

Re: #31: @mattp_160 - Very low. Google what float means and then

Matty what makes you think MTST is a legit stockinvestment?

airjay

03/01/14 6:04 PM

Post #33

how come yahoo finance doesn't have a messageboard for MTST?

holdithigh Free

03/01/14 11:13 AM

Post #32

Re: #31: @mattp_160 - Very low. Google what float means and then

hey matt.

I like the look of this stock. I purchased some yesterday and will continue to nibble throughout the year. Very low volume has really caught my eye. Also the share holders on record (the major ones) are not dumping their shares in the mid $1.50's

Dilution should continue until revenue kicks in next year. that should be very expected as they have bills to pay.

I've did some research, don't really like their business address. It appears it's in an office of a past church or some type of christian library. I would assume it's just a local location among the board members and they only show 3 employee's.

This could play out to be very nice investment as long as they don't get carried away with dilution of stock.

average volume of 26k a day is unheard of with a price of $1.50 ish

good luck and if you see anything else in the way of news, share it, i will.

hold

mattp_160

02/27/14 9:30 PM

Post #31

Re: #30: @airjay - float of 12.61 considered high or low?

Very low. Google what float means and then you'll understand. This has crazy swings because the volume is so low.

I'm adding more shares tomorrow. Once there drug hits this market this thing is going crazy.

airjay

02/27/14 2:54 AM

Post #30

Re: #29: @mattp_160 - Does this really have a float of 12.61

float of 12.61 considered high or low?

mattp_160

02/26/14 11:06 PM

Post #29

Does this really have a float of 12.61 million? Yahoo finance has it sitting at that..

Madkins

02/26/14 7:19 AM

Post #28

MONTCLAIR, NJ -- (Marketwired) -- 02/26/14 -- MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California. MetaStat will be presenting on Wednesday, March 12, 2014 at 12:30 pm (PT).

MetaStat's Chief Executive Officer, Oscar Bronsther, M.D., will present an overview of the company and provide an update on MetaStat's novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.

Dr. Bronsther stated, "With our recently completed MetaSite Breast? trial and the opening of our drug discovery laboratory, we believe we are well positioned to deliver our breast cancer diagnostics to the market in 2015 and validate our novel drug targets." Dr. Bronsther continued, "We believe this is a great opportunity to create visibility and investor awareness for our company and we are excited to have the opportunity to present at the ROTH Conference."

To arrange a one-on-one meeting with management, please contact Robert Haag at mtst@irthcommunications.com or 1-866-976-4784.
About the 26th Annual ROTH Conference The annual ROTH Conference is one of the largest of its kind in the U.S., bringing together executives from hundreds of growth companies. This event is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including Cleantech, Consumer

airjay

02/26/14 1:12 AM

Post #27

Re: #25: @mattp_160 - nope, no pump and dump here. Volume is

That's good to hear. How reliable do you think MTST is?

Older

MetaStat Inc. (MTST)

Followers	9	Posters	16
Posts (Today)	0	Posts (Total)	76
Created	02/18/14	Type	Free
Moderators

http://www.metastat.com/

150,000,000 shares authorized; 21,469,435 and 21,054,418 shares issued and outstanding respectively

MetaStat, Inc. (OTCQB: MTST) is a development stage life sciences company headquartered in Montclair, New Jersey. We are focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis - cancer that spreads from a primary tumor through the bloodstream to other areas of the body. Systemic metastasis is responsible for ~90% of all solid tumor cancer related deaths and as such, we believe that more effective treatment of metastatic disease and/or the prevention of systemic metastasis is needed to improve patient outcomes.

Our licensed proprietary platform technologies are based on the identification of a common pathway for the development of metastatic disease in solid epithelial-based tumors. These discoveries are the result of over 15 years of collaboration with four scientific/academic institutions that enabled us to understand the underlying biology and mechanisms of systemic metastasis. Central to these discoveries are i) the “MetaSite™,” the micro-anatomical site, or “window” in the blood vessels that metastatic cells squeeze through to enter the blood stream to begin their deadly spread, and ii) the pivotal role of the Mena protein and its isoforms in the metastatic cascade.

We are developing two function-based diagnostic product lines, MetaSite Breast™ and MenaCalc™. The MetaSite Breast™ test measures the process of systemic metastasis and is intended for early stage breast cancer patients. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. Both our MetaSite Breast™ and MenaCalc™ diagnostics are designed to accurately predict the probability of systemic metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of systemic metastasis who need aggressive therapy and by sparing patients with a low-risk of systemic metastasis from the harmful side effects and expense of chemotherapy.

Additionally, we are developing our MenaBloc™ therapeutic platform, with the goal of discovering inhibitors of key pathways that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.

Douglas A. Hamilton, B.Sc., MBA
President and Chief Executive Officer
Mr. Hamilton was appointed President and Chief Executive Officer of the company on June 17, 2015 and has consulted for the company as acting Chief Financial Officer since August 2014. Mr. Hamilton has over 20 years experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as CFO for SEA Medical Systems, a Silicon Valley health-tech company that developed medical devices designed to enhance patient safety by preventing medication errors. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing, Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox^® and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend^® and Zithromax^® product teams at Pfizer, in addition to the Aranesp^®, Epogen^®, Stemgen^®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.

Michael J. Donovan, PhD, MD
Chief Medical Officer
Dr. Donovan joined the company as acting chief medical officer in August 2015. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid-based assays and coupled mathematic applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.
In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of Exosome Diagnostics, Inc. and Chief Scientific Officer for Aureon Biosciences Corporation.
Dr. Donovan graduated from Rutgers University with a BS in zoology, a MS in endocrinology and a PhD in cell and developmental biology. He received his MD from the University of Medicine and Dentistry of New Jersey.
Mark Gustavson, Ph.D.
Vice President of Diagnostics
Dr. Gustavson joined the company as Vice President of Diagnostics in August 2014. Dr. Gustavson has more than 10 years of experience in translational oncology, biomarker and diagnostics development, and quantitative pathology. Prior to joining the company, Dr. Gustavson was a Consultant for Oncology Biomarker Development at Genoptix Medical Laboratory. From 2006 to 2012, Dr. Gustavson was with HistoRx, Inc. where he played a central role in the development and commercialization of the quantitative pathology platform, AQUA® Technology. With HistoRx, Dr. Gustavson served as Director of Operations where he oversaw assay and platform development as well as clinical validation of the breast cancer diagnostic test, IHC4. Dr. Gustavson did his post-doctoral fellowship at Yale University and received his Ph.D. in Cancer Biology from Vanderbilt University School of Medicine. Dr. Gustavson has over 40 peer-review publications and abstracts, and 9 patents.

Daniel H. Schneiderman
Vice President of Finance & Corporate Secretary
Daniel H. Schneiderman was appointed Vice President of Finance effective December 21, 2012 and has served as the company's Vice President, Comptroller and Corporate Secretary since February 27, 2012. Mr. Schneiderman has over ten years of investment banking and corporate finance experience, focusing on private and public equity for small and mid-market capitalization companies mainly in the healthcare and life sciences sectors. Prior to joining the company, he was senior vice president of investment banking for Burnham Hill Partners LLC, where he worked since 2008. From 2004 through 2008, Mr. Schneiderman was vice president of investment banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, he worked at H.C. Wainwright & Co. in 2004 as an analyst. Mr. Schneiderman holds a Bachelor's Degree from Tulane University.

Heiner Dreismann, Ph.D.
Diagnostic Consultant
Dr. Dreismann joined the company as a consultant (head of diagnostics) in October 2013. Dr. Dreismann is a seasoned executive with more than 24 years of experience in the health care industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.